How long should children with spasticity take Vigabatrin (Ocoda)?

Vigabatrin (Vigabatrin) is an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T). It can increase the concentration of GABA in the brain, thereby exerting an anticonvulsant effect. The drug is widely used to treat spasticity in children (especially cases related to tuberous sclerosis) and refractory epilepsy. Because of its proven efficacy, it is often used as a first-line or important alternative treatment.

In the treatment of spasticity in children, the duration of treatment with Vigabatrin is usually shorter. International guidelines and clinical practice generally recommend a trial period of 2 weeks to 4 weeks. If the child has an obvious response to the drug (such as a reduction in convulsions or an improvement in EEG), the treatment can be continued; if the effect is not significant, the drug should be stopped in time and other options should be considered. For some children who are highly sensitive to drugs and have obvious benefit, the treatment course may be extended to several months, but long-term high-dose use is generally not recommended.

While patients with childhood spasticity are taking Vigabatrin, doctors will judge the efficacy through clinical observation and electroencephalogram (EEG) monitoring. Once the spasticity is effectively controlled, the medication is usually gradually tapered and discontinued to avoid the side effects of long-term medication, especially the risk of retinal damage. If there is no significant improvement after several weeks of treatment, the drug should be discontinued as soon as possible to avoid delaying other treatment opportunities.

It needs to be emphasized that there is no uniform"fixed duration" for Vigabatrin treatment, and it should be individually adjusted based on the child's clinical response, tolerance and EEG improvement. Throughout the course of treatment, children need to receive regular eye examinations and neurological follow-up to monitor vision, development and epilepsy control. Generally speaking, Vigabatrin is mostly a short-term treatment, and the course of treatment is generally controlled between a few weeks to a few months. The final withdrawal time is determined by professional doctors based on the dynamics of the efficacy.

Reference link:https://www.drugs.com